BioMatrix Specialty Pharmacy Awarded Preferred Bleeding Disorder Provider Status By AscellaHealth
PLANTATION, Fla., July 13, 2020 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today preferred network status for AscellaHealth's bleeding disorder patient population. The decision to include BioMatrix in the PBM's national network was based on overall clinical expertise and extensive bleeding disorder experience, operational efficiencies, data reporting capabilities, and competitive pricing model. Beginning July 1, 2020, BioMatrix became one of just four specialty pharmacies selected by the PBM to hold preferred provider status.
AscellaHealth is a national Specialty PBM serving commercial, Medicare, and Medicaid plans. The rapidly growing organization includes over 1 million covered lives and has earned a name by providing high quality care for patients and substantial cost savings for plan sponsors. "We are excited to be working with BioMatrix to support our patients with bleeding disorders and look forward to continuing to provide innovative service models." Stated Dea Belazi, President & CEO of AscellaHealth
"BioMatrix and AscellaHealth share the same patient-centric approach and an ongoing commitment to meeting and exceeding the needs of patients and other healthcare stakeholders," stated Nick Karalis CEO of BioMatrix. "We are very excited about our expanding partnership and look forward to providing outstanding service to AscellaHealth's bleeding disorder patient population."
For more information about BioMatrix, please visit www.biomatrixsprx.com.
About BioMatrix Specialty Pharmacy
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomatrix-specialty-pharmacy-awarded-preferred-bleeding-disorder-provider-status-by-ascellahealth-301092287.html
SOURCE BioMatrix Specialty Pharmacy